Broad biomarker access enables preventive action
PrimaryFunction Health's core theory is that making a broad panel of lab tests accessible on a membership basis lets people identify physiological abnormalities earlier than conventional episodic care. The causal mechanism is information access: repeated measurement across many biomarkers reveals risks or dysfunctions that would otherwise remain hidden until symptoms or disease appear. Testable predictions are that members receiving 160+ lab tests will have more early detection of cardiometabolic, hormonal, inflammatory, nutritional, renal, hepatic, or other abnormalities than comparable people receiving standard care, and that those findings will lead to earlier interventions.
Popperian evaluation
The premise is credible: if a person measures 160 or more biomarkers repeatedly, they will almost certainly see more abnormal values than someone getting narrower episodic care. The biological mechanism is plain information capture, not a speculative pathway. The weak point is actionability. More measurements can find real disease earlier, but they can also find transient, borderline, or clinically useless abnormalities.
Supporting evidence: The theory specifies repeated measurement across many biomarkers outside conventional episodic care.; The prediction names broad abnormality classes: cardiometabolic, hormonal, inflammatory, nutritional, renal, hepatic, and other physiological findings.; The evidence context treats increased biomarker information access as high confidence.
Counter evidence: No direct outcome data are provided showing that Function Health members detect disease earlier than matched standard-care controls.; The actionability assumption is only medium confidence.; The supplied publication is an autophagy assay guideline and does not directly support broad consumer lab screening.
The theory can explain why members would receive more abnormal lab findings: they are tested more often and across more analytes. That is almost arithmetic. It does less work explaining whether those findings are clinically useful or whether later interventions improve outcomes. A competing explanation is simple ascertainment: test more, label more, intervene more, without proving better prevention.
Supporting evidence: The causal claim links broader and repeated testing to more information about physiological states.; The theory predicts higher rates and earlier timing of abnormality detection compared with standard care.; The proposed evaluation compares members with similar people receiving standard care.
Counter evidence: The evidence context does not include observed member outcomes, matched controls, intervention rates, or disease endpoints.; More detected abnormalities could reflect overtesting, false positives, normal biological variation, or threshold effects.; The theory does not yet separate useful early detection from detection that would never change health outcomes.
This is testable. A matched cohort or randomized design could ask whether members receiving 160 or more tests have earlier detection of prespecified abnormalities, earlier interventions, and fewer later clinical events than standard-care controls. The theory would take a real hit if broad testing only increases minor abnormal flags without earlier clinically justified treatment.
Supporting evidence: The prediction specifies a comparison group: comparable people receiving standard care.; The outcome can be measured as rates and timing of abnormality detection.; A second outcome is specified: whether detected abnormalities lead to earlier interventions.
Counter evidence: The theory needs tighter prespecified thresholds for what counts as clinically relevant abnormality.; It does not define the follow-up window needed to judge whether earlier intervention changed outcomes.; Without matching or randomization, healthier, wealthier, or more health-seeking members could bias the result.
Reasoning tree
Public endorsements
The provided evidence does not show Andrew Huberman publicly stating a view on this theory. There are no quotes from him, and the lone record is a Function-hosted page about a Huberman Lab episode with mostly site and disclaimer text, not a clear endorsement, discussion, or contradiction of broad biomarker testing for earlier preventive action.
Silent. The provided evidence contains no quotes from Azra Raza and no publication tied to her discussing Function Health's theory that broad recurring biomarker testing enables earlier detection and intervention. The listed clinical trial records are unrelated to Function Health, preventive lab testing, or Raza's public views.
The evidence only shows Daniel Sodickson as Function Health's Chief Medical Scientist through an executive bio record. It does not include any public quote, publication, or statement from him about broad biomarker testing, early detection, or preventive action. Employment alone is not a public endorsement of this specific theory.
No public quotes, records, or publications are provided for Danna Chung on this theory, so there is no evidence here that she endorses it, mentions it, or contradicts it.
The record shows Dan Swerdlin is a co-founder and general counsel of Function Health, and Function publicly claims access to broad testing supports long healthy lives. It does not show Dan Swerdlin himself publicly stating, endorsing, or disputing the specific theory that broad biomarker access enables earlier preventive action.